Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-Infusion of Donor Lymphocytes With CD3-Depleted HSCT for GVHD Prevention in Children
NCT07366801Phase 3Recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Peptides, Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of cyclosporine, sirolimus, ruxolitinib, abatacept in graft-versus-host disease (GVHD), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Started Sep 2025; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07366801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07366801.